X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9188) 9188
Newsletter (741) 741
Publication (569) 569
Book Review (138) 138
Newspaper Article (138) 138
Book Chapter (43) 43
Magazine Article (37) 37
Conference Proceeding (10) 10
Trade Publication Article (6) 6
Dissertation (5) 5
Book / eBook (4) 4
Transcript (4) 4
Web Resource (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
adalimumab (8540) 8540
humans (6079) 6079
index medicus (4580) 4580
infliximab (4231) 4231
female (3603) 3603
male (3366) 3366
adult (2792) 2792
middle aged (2770) 2770
tumor necrosis factor-alpha - antagonists & inhibitors (2736) 2736
etanercept (2661) 2661
treatment outcome (2195) 2195
rheumatology (2174) 2174
antibodies, monoclonal - therapeutic use (2104) 2104
rheumatoid arthritis (1812) 1812
arthritis, rheumatoid - drug therapy (1750) 1750
antirheumatic agents - therapeutic use (1738) 1738
antibodies, monoclonal, humanized (1670) 1670
therapy (1403) 1403
aged (1370) 1370
psoriasis (1302) 1302
antibodies, monoclonal, humanized - therapeutic use (1273) 1273
dermatology (1247) 1247
gastroenterology & hepatology (1242) 1242
care and treatment (1193) 1193
rheumatoid-arthritis (1136) 1136
efficacy (1092) 1092
arthritis (1042) 1042
double-blind (1037) 1037
drug therapy (1008) 1008
anti-inflammatory agents - therapeutic use (1000) 1000
crohn's disease (988) 988
adalimumab - therapeutic use (985) 985
methotrexate (969) 969
antibodies, monoclonal - adverse effects (957) 957
crohn disease - drug therapy (953) 953
tumor necrosis factor (953) 953
severity of illness index (947) 947
immunoglobulin g - therapeutic use (905) 905
receptors, tumor necrosis factor - therapeutic use (902) 902
research (846) 846
safety (840) 840
psoriasis - drug therapy (810) 810
young adult (797) 797
antirheumatic agents - adverse effects (796) 796
retrospective studies (784) 784
crohns-disease (757) 757
inflammatory-bowel-disease (747) 747
pharmacology & pharmacy (733) 733
adolescent (671) 671
drug therapy, combination (652) 652
inflammatory bowel disease (652) 652
medicine & public health (651) 651
analysis (649) 649
rheumatoid factor (638) 638
risk factors (637) 637
medical research (629) 629
ulcerative colitis (610) 610
immunotherapy (605) 605
medicine, experimental (592) 592
antibodies, monoclonal, humanized - adverse effects (571) 571
tumor necrosis factor-tnf (568) 568
monoclonal antibodies (552) 552
methotrexate - therapeutic use (548) 548
abridged index medicus (530) 530
disease (520) 520
dosage and administration (513) 513
trial (508) 508
immunosuppressive agents - therapeutic use (501) 501
follow-up studies (494) 494
infliximab - therapeutic use (494) 494
patients (493) 493
time factors (477) 477
remission induction (473) 473
immunology (471) 471
prospective studies (464) 464
remission (457) 457
certolizumab pegol (445) 445
antibodies, monoclonal - administration & dosage (444) 444
monoclonal-antibody (439) 439
medicine, general & internal (429) 429
clinical trials (426) 426
anti-inflammatory agents - adverse effects (422) 422
health aspects (407) 407
immunoglobulin g - adverse effects (407) 407
biological products - therapeutic use (403) 403
placebo-controlled trial (401) 401
psoriatic arthritis (401) 401
ankylosing spondylitis (397) 397
arthritis, psoriatic - drug therapy (397) 397
antirheumatic agents - administration & dosage (393) 393
anti-tnf (389) 389
complications and side effects (388) 388
adalimumab - adverse effects (387) 387
inflammation (386) 386
tumor necrosis factor-alpha - immunology (385) 385
biologics (374) 374
quality of life (374) 374
antibodies (366) 366
necrosis-factor-alpha (363) 363
management (362) 362
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9263) 9263
Spanish (182) 182
German (164) 164
French (151) 151
Korean (79) 79
Japanese (70) 70
Russian (44) 44
Polish (37) 37
Italian (36) 36
Hungarian (27) 27
Portuguese (25) 25
Danish (19) 19
Czech (16) 16
Turkish (16) 16
Dutch (8) 8
Croatian (7) 7
Chinese (5) 5
Slovak (4) 4
Swedish (3) 3
Finnish (2) 2
Arabic (1) 1
Hebrew (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Revista Espanola de Enfermadades Digestivas (REED), ISSN 1130-0108, 09/2019, Volume 111, Issue 9, p. 721
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 09/2019, Volume 17, Issue 9, pp. 936 - 939
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 05/2016, Volume 22, Issue 8, pp. 1999 - 2015
Background:Biological tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of inflammatory bowel disease and redefined treatment goals to... 
certolizumab pegol | TNF inhibitor | infliximab | Crohn's disease | adalimumab | golimumab | inflammatory bowel disease | antibodies | pharmacodynamic | ulcerative colitis | pharmacokinetic | loss of response | therapeutic drug monitoring | personalized therapy | NECROSIS-FACTOR ANTAGONISTS | THERAPEUTIC MONOCLONAL-ANTIBODIES | INFLIXIMAB TREATMENT FAILURE | REGULATORY T-CELLS | C-REACTIVE PROTEIN | RHEUMATOID-ARTHRITIS PATIENTS | MANAGING SECONDARY LOSS | FACTOR-ALPHA ANTAGONISTS | PLACEBO-CONTROLLED TRIALS | ACTIVE ULCERATIVE-COLITIS | GASTROENTEROLOGY & HEPATOLOGY | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Infliximab - therapeutic use | Infliximab - pharmacokinetics | Antibodies, Monoclonal - blood | Immunosuppressive Agents - blood | Adalimumab - blood | Treatment Failure | Adalimumab - pharmacokinetics | Certolizumab Pegol - pharmacokinetics | Certolizumab Pegol - therapeutic use | Infliximab - blood | Antibodies, Monoclonal - immunology | Certolizumab Pegol - blood | Certolizumab Pegol - immunology | Inflammatory Bowel Diseases - drug therapy | Adalimumab - immunology | Antibodies, Monoclonal - pharmacokinetics | Infliximab - immunology | Adalimumab - therapeutic use | Immunosuppressive Agents - immunology | Antibodies - blood | Drug Monitoring | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Journal Article
by Nakase, H and Motoya, S and Matsumoto, T and Watanabe, K and Hisamatsu, T and Yoshimura, N and Ishida, T and Kato, S and Nakagawa, T and Esaki, M and Nagahori, M and Matsui, T and Naito, Y and Kanai, T and Suzuki, Y and Nojima, M and Watanabe, M and Hibi, T and Andoh, Akira and Ashida, Toshifumi and Endo, Katsuya and Endo, Yutaka and Esaki, Motohiro and Fujita, Hiroshi and Fujiya, Mikihiro and Haruma, Ken and Hibi, Toshifumi and Hiraoka, Sakiko and Hirata, Ichiro and Hisamatsu, Tadakazu and Honda, Yutaka and Iijima, Hideki and Iizuka, Bunei and Ikeya, Kentaro and Inoue, Takuya and Inoue, Shuji and Ishida, Tetsuya and Ishiguro, Yo and Ishihara, Shunji and Ito, Hiroaki and Iwakiri, Ryuichi and Kagaya, Takashi and Kanai, Takanori and Kashida, Hiroshi and Kato, Shingo and Kato, Jun and Katsurada, Takehiko and Kinjyo, Fukunori and Kobayashi, Kiyonori and Kodama, Mayumi and Kunisaki, Reiko and Kurahara, Koichi and Kurokami, Takafumi and Kyouwon, Lee and Matsuda, Koichiro and Matsueda, Kazuhiro and Matsui, Toshiyuki and Matsumoto, Takayuki and Mitsuyama, Keiichi and Mizokami, Yuji and Motoya, Satoshi and Naito, Yuji and Nakagawa, Tomoo and Nakamura, Shiro and Nakase, Hiroshi and Nojima, Masanori and Nomura, Masafumi and Ogawa, Atsuhiro and Okazaki, Kazuichi and Otsuka, Kazuaki and Sakuraba, Hirotake and Saruta, Masayuki and Sasaki, Makoto and Shirai, Takayuki and Suga, Tomoaki and Sugimura, Kazuhito and Sugiyama, Toshiro and Suzuki, Yasuo and Takeshima, Fuminao and Tamaki, Hiroyuki and Tanaka, Shinji and Tanida, Satoshi and Tominaga, Keiichi and Tomizawa, Taku and Watanabe, Kenji and Watanabe, Mamoru and Yamamoto, Shojiro and Yamashita, Masaki and Yoshida, Atsushi and Yoshimura, Naoki and DIAMOND Study Grp and DIAMOND study group
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 11/2017, Volume 46, Issue 9, pp. 873 - 882
Summary Background Significance of monitoring adalimumab trough levels and anti‐adalimumab antibodies (AAA) for disease outcome in Crohn's disease (CD)... 
RHEUMATOID-ARTHRITIS | MAINTENANCE | INFLAMMATORY-BOWEL-DISEASE | 6-THIOGUANINE NUCLEOTIDE | IMMUNOMODULATORS | COMBINATION THERAPY | ULCERATIVE-COLITIS | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-RESPONSE | Guanine Nucleotides - blood | Adalimumab - immunology | Thionucleotides - blood | Humans | Anti-Inflammatory Agents - immunology | Male | Treatment Outcome | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - therapeutic use | Mercaptopurine - therapeutic use | Adalimumab - blood | Crohn Disease - blood | Crohn Disease - drug therapy | Sensitivity and Specificity | Adalimumab - pharmacokinetics | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - pharmacokinetics | Antibodies - blood | Female | Drug Therapy, Combination | Mercaptopurine - analogs & derivatives | Measurement | Viral antibodies | Medical research | Analysis | Medicine, Experimental | Antibodies | Biopharmaceutics | Blood cells | Body weight | Erythrocytes | Diamonds | Crohn's disease | Pharmacology | Regression analysis | Thioguanine | Patients | Crohns disease | Sensitivity | Regression models | Red blood cells | Multiple regression models | Predictions | Monoclonal antibodies | Remission | Pharmacokinetics | Original | Personalised Adalimumab Pharmacokinetics
Journal Article
Journal Article
Rheumatology, ISSN 1462-0324, 02/2019, Volume 58, Issue Supplement_1, pp. i1 - i3
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 11/2013, Volume 13, Issue 11, pp. 1599 - 1611
Introduction: Following its marketing authorization for the treatment of ankylosing spondylitis (AS) in 2006 in the United States und in the European Union,... 
nonradiographic axial spondyloarthritis | tumor necrosis factor α | adalimumab | ankylosing spondylitis | Adalimumab | Nonradiographic axial spondyloarthritis | Ankylosing spondylitis | Tumor necrosis factor α | MEDICINE, RESEARCH & EXPERIMENTAL | FACTOR ANTAGONIST THERAPY | SHORT-TERM IMPROVEMENT | OF-LIFE OUTCOMES | SOCIETY CLASSIFICATION CRITERIA | RADIOGRAPHIC PROGRESSION | RHEUMATOLOGY BIOLOGICS REGISTER | TNF-ALPHA INHIBITORS | tumor necrosis factor alpha | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | OPEN-LABEL TRIAL | PLACEBO-CONTROLLED TRIAL | NECROSIS-FACTOR BLOCKERS | Spondylarthritis - diagnostic imaging | Clinical Trials as Topic - statistics & numerical data | Antirheumatic Agents - administration & dosage | United States | Humans | Spondylarthritis - drug therapy | Spondylarthritis - pathology | Biological Products - pharmacology | Drug Approval | Infection - etiology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacology | Antirheumatic Agents - adverse effects | Biological Products - adverse effects | Antirheumatic Agents - pharmacology | Spine - pathology | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Antibodies, Monoclonal, Humanized - adverse effects | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Antibodies, Monoclonal, Humanized - therapeutic use | Disease Susceptibility | Double-Blind Method | Spondylitis, Ankylosing - drug therapy | Treatment Outcome | Disease Progression | Spondylitis, Ankylosing - diagnostic imaging | Radiography | Spine - diagnostic imaging | European Union | Biological Products - administration & dosage | Spondylitis, Ankylosing - pathology | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article